The axis age-rage-soluble rage and oxidative stress in chronic nkidney disease

Advances in Experimental Medicine and Biology

Volumn 824, Issue , 2014, Pages 191-208

  Gugliucci, Alejandro ^a   Menini, Teresita ^a  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Advanced glycation; AGE receptor; Atherosclerosis; Cardiovascular disease; Hemodialysis; Nephropathy; Oxidative stress; Renal failure

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; AMINOGUANIDINE; BENFOTIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIAMINE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; MOK PROTEIN, HUMAN; TUMOR ANTIGEN;

ARTICLE; AUTOFLUORESCENCE; BIOACCUMULATION; BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CHRONIC KIDNEY DISEASE; CUTANEOUS PARAMETERS; DIABETIC NEPHROPATHY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; END STAGE RENAL DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HEMODIALYSIS PATIENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MESANGIUM CELL; NEPHRITIS; OXIDATIVE STRESS; PODOCYTE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SKIN AUTOFLUORESCENCE; ANIMAL; CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY; MITOGEN-ACTIVATED PROTEIN KINASES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84921652333     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-07320-0_14     Document Type: Article

References (122)

1. Smit AJ, Gerrits EG. Skin autofl uorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:527–33
2. Koyama H, Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest. 2010;40:623–35
3. Thallas-Bonke V, Coughlan MT, Tan AL, Harcourt BE, Morgan PE, Davies MJ, et al. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation endproduct content. Nephrology (Carlton). 2013;18:47–56
4. Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, Rakhorst G, et al. Advanced glycation end-products and skin autofl uorescence in end-stage renal disease: a review. Clin Chem Lab Med. 2013;4:1–10
5. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3:101–8
6. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep. 2000;2:430–6
7. Jerums G, Panagiotopoulos S, Forbes J, Osicka T, Cooper M. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys. 2003;419:55–62
8. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38(4 Suppl 1):S100–6
9. Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int. 1996;49:1795–804
10. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia. 1996;39:149–60
11. Vlassara H. Advanced glycation in diabetic renal and vascular disease. Kidney Int Suppl. 1995;51:S43–4
12. Dyer DG, Blackledge JA, Katz BM, Hull CJ, Adkisson HD, Thorpe SR, et al. The Maillard reaction in vivo. Z Ernahrungswiss. 1991;30:29–45
13. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173:932–9
14. Watkins NG, Neglia-Fisher CI, Dyer DG, Thorpe SR, Baynes JW. Effect of phosphate on the kinetics and specificity of glycation of protein. J Biol Chem. 1987;262:7207–12
15. Thornalley PJ. Advanced glycation end products in renal failure. J Ren Nutr. 2006;16:178–84
16. Thornalley PJ. Glycation free adduct accumulation in renal disease: the new AGE. Pediatr Nephrol. 2005;20:1515–22
17. Brouwers O, Niessen PM, Miyata T, Ostergaard JA, Flyvbjerg A, Peutz-Kootstra CJ, et al. Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia. 2014;57:224–35
18. Vlassara H, Torreggiani M, Post JB, Zheng F, Uribarri J, Striker GE. Role of oxidants/infl ammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl. 2009;114:S3–11
19. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. 2008;3:691–8
20. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728–31
21. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis. 2003;42:532–8
22. Gugliucci A, Bendayan M. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem. 1995;43:591–600
23. Popolo A, Autore G, Pinto A, Marzocco S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic Res. 2013;47:346–56
24. Bowman MA, Schmidt AM. The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular infl ammation. J Mol Med (Berl). 2013;91:1329–31
25. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids. 2012;42:1151–61
26. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, et al. Maillard reactionmediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 1992;41 Suppl 2:36–41
27. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest. 1993;91:2463–9
28. Lee AT, Cerami A. Role of glycation in aging. Ann N Y Acad Sci. 1992;663:63–70
29. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad SciU S A. 1994; 91:9441–5
30. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad SciU S A. 1997;94:13915–20
31. Thornalley PJ, Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial. 2009;22:400–4
32. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem. 1991;266:11649–53
33. Sell DR, Nagaraj RH, Grandhee SK, Odetti P, Lapolla A, Fogarty J, et al. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev. 1991;7:239–51
34. Hricik DE, Schulak JA, Sell DR, Fogarty JF, Monnier VM. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int. 1993;43:398–403
35. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol. 2005;16:1471–85
36. Rabbani N, Sebekova K, Sebekova Jr K, Heidland A, Thornalley PJ. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int. 2007;72:1113–21
37. RabbaniN, Thornalley PJ. Quantitation of markers of protein damage by glycation, oxidation, and nitration in peritoneal dialysis. Perit Dial Int. 2009; 29 Suppl 2:S51–6
38. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia. 2010; 53:1506–16
39. Kihm LP, Muller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol. 2011;22:914–26
40. Mallipattu SK, He JC, Uribarri J. Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients. Semin Dial. 2012;25:529–38
41. Kim YL, Cho JH, Choi JY, Kim CD, Park SH. Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution. J Ren Nutr. 2013;23:218–22
42. Vlassara H. Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif. 1994;12:54–9
43. Horl WH. Genesis of the uraemic syndrome: role of uraemic toxins. Wien Klin Wochenschr. 1998; 110:511–20
44. Gugliucci A, Kinugasa E, Ogata H, Caccavello R, Kimura S. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL fraction and VLDL. Clin Chim Acta. 2013;430C:9–14
45. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta. 2007; 377:213–20
46. Wihler C, Schafer S, Schmid K, Deemer EK, Munch G, Bleich M, et al. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensinconverting enzyme and vasopeptidase inhibition. Diabetologia. 2005;48:1645–53
47. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53
48. Coughlan MT, Mibus AL, Forbes JM. Oxidative stress and advanced glycation in diabetic nephropathy. Ann N Y Acad Sci. 2008;1126:190–3
49. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol. 2002;58 Suppl 1:S12–9
50. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002;15:336–41
51. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996;98:1088–94
52. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes. 1996;45 Suppl 3:S77–80
53. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656–66
54. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res. 2003;23:129–34
55. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, Lindholm B, et al. Enhanced RAGE-mediated NFkappaB stimulation in infl amed hemodialysis patients. Atherosclerosis. 2005;180:333–40
56. Coughlan MT, Cooper ME, Forbes JM. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid Redox Signal. 2007;9:331–42
57. Daffu G, del Pozo CH, O’Shea KM, Ananthakrishnan R, Ramasamy R, Schmidt AM. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci. 2013;14:19891–910
58. Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, et al. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int. 2012;82:759–70
59. Yamamoto Y, Yamamoto H. Interaction of receptor for advanced glycation end products with advanced oxidation protein products induces podocyte injury. Kidney Int. 2012;82:733–5
60. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci. 2011;1243:88–102
61. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106:842–53
62. Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes. 2010;59:2043–54
63. D’Agati V, Yan SF, Ramasamy R, Schmidt AM. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab. 2010;21:50–6
64. D’Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol. 2010;6:352–60
65. Cottone S, Lorito MC, Riccobene R, Nardi E, Mule G, Buscemi S, et al. Oxidative stress, infl ammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008;21:175–9
66. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinfl ammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:2213–9
67. Kalousova M, Jachymova M, Mestek O, Hodkova M, Kazderova M, Tesar V, et al. Receptor for advanced glycation end products–soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant. 2007;22:2020–6
68. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005;16:2363–72
69. Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, et al. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2012;22:748–55
70. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol. 2010;79:1379–86
71. Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Moure-Gonzalez M, Seoane-Blanco A, Varela-Roman A, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail. 2010;12:1092–100
72. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009;4:389–401
73. Sung JY, Chung W, Kim AJ, Kim HS, Ro H, Chang JH, et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2013;230:59–66
74. Zakiyanov O, Kalousova M, Kriha V, Zima T, Tesar V. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic infl ammatory disease. Kidney Blood Press Res. 2011;34:457–64
75. Menini T, Ikeda H, Kimura S, Gugliucci A. Circulating soluble RAGE increase after a cerebrovascular event. Clin Chem Lab Med. 2014;52:109–16
76. Mahajan N, Mahmood S, Jain S, Dhawan V. Receptor for advanced glycation end products (RAGE), infl ammatory ligand EN-RAGE and soluble RAGE (sRAGE) in subjects with Takayasu’s arteritis. Int J Cardiol. 2013;168:532–4
77. Fujisawa K, Katakami N, Kaneto H, Naka T, Takahara M, Sakamoto F, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227:425–8
78. Falcone C, Bozzini S, Guasti L, D’Angelo A, Capettini AC, Paganini EM, et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. ScientificWorldJournal. 2013;2013:584504
79. Skrha Jr J, Kalousova M, Svarcova J, Muravska A, Kvasnicka J, Landova L, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:277–81
80. Sourris KC, Morley AL, Koitka A, Samuel P, Coughlan MT, Penfold SA, et al. Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin IItype 2 (AT2) receptor. Diabetologia. 2010;53:2442–51
81. Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, et al. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism. 2012;61:1067–72
82. Tang SC, Chan LY, Leung JC, Cheng AS, Lin M, Lan HY, et al. Differential effects of advanced glycation end-products on renal tubular cell infl ammation. Nephrology (Carlton). 2011;16:417–25
83. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs. 2008;17:983–96
84. Gada E, Owens AW, Gore MO, See R, Abdullah SM, Ayers CR, et al. Discordant effects of rosiglitazone on novel infl ammatory biomarkers. Am Heart J. 2013;165:609–14
85. Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular infl ammation. Curr Vasc Pharmacol. 2010;8:86–92
86. Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL, et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia. 2007;50:1819–25
87. Daroux M, Prevost G, Maillard-Lefebvre H, Gaxatte C, D’Agati VD, Schmidt AM, et al. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 2010;36:1–10
88. Harcourt BE, Sourris KC, Coughlan MT, Walker KZ, Dougherty SL, Andrikopoulos S, et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int. 2011;80:190–8
89. Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest. 2010;40:742–55
90. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic infl ammatory diseases. Rheumatology (Oxford). 2009;48:1190–6
91. Nishizawa Y, Koyama H. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease. J Ren Nutr. 2008;18:76–82
92. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinfl ammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012;220:208–14
93. Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamato H, Kurokawa K, et al. A severe diabetic nephropathy model with early development of nodule- like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes. 2006;55:356–66
94. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, et al. Skin autofl uorescence is associated with the progression of chronic kidney disease: a prospective observational study. PLoS One. 2013;8:e83799
95. Susantitaphong P, Siribamrungwong M, Jaber BL. Convective therapies versus low-fl ux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2013;28:2859–74
96. Mac-Way F, Couture V, Utescu MS, Ignace S, De Serres SA, Loignon RC, et al. Advanced glycation end products, aortic stiffness, and wave refl ection in peritoneal dialysis as compared to hemodialysis. Int Urol Nephrol. 2014;46(4):817–24
97. Crowley LE, Johnson CP, McIntyre N, Fluck RJ, McIntyre CW, Taal MW, et al. Tissue advanced glycation end product deposition after kidney transplantation. Nephron Clin Pract. 2013;124:54–9
98. Makulska I, Szczepanska M, Drozdz D, Polak- Jonkisz D, Zwolinska D. Skin autofl uorescence as a marker of cardiovascular risk in children with chronic kidney disease. Pediatr Nephrol. 2013;28:121–8
99. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes. 2012; 61:549–59
100. Lunceford N, GugliucciA. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea. Fitoterapia. 2005;76:419–27
101. Gugliucci A, Bastos DH, Schulze J, Souza MF. Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia. 2009;80:339–44
102. Gugliucci A, Menini T. The polyamines spermine and spermidine protect proteins from structural and functional damage by AGE precursors: a new role for old molecules? Life Sci. 2003;72:2603–16
103. Gugliucci A, Menini T. The botanical extracts of Achyrocline satureoides and Ilex paraguariensis prevent methylglyoxal-induced inhibition of plasminogen and antithrombin III. Life Sci. 2002; 72:279–92
104. SriHarsha PS, Gardana C, Simonetti P, Spigno G, Lavelli V. Characterization of phenolics, in vitro reducing capacity and anti-glycation activity of red grape skins recovered from winemaking byproducts. Bioresour Technol. 2013;140:263–8
105. Saraswat M, Reddy PY, Muthenna P, Reddy GB. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br J Nutr. 2009;101:1714–21
106. Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR, Haqqi TM. Green tea polyphenol epigallocatechin- 3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther. 2009;11:R71
107. Babu PV, Sabitha KE, ShyamaladeviCS. Effect of green tea extract on advanced glycation and crosslinking of tail tendon collagen in streptozotocin induced diabetic rats. Food Chem Toxicol. 2008;46:280–5
108. Ouyang P, Peng WL, Xu DL, Lai WY, Xu AL. Green tea polyphenols inhibit advanced glycation end product-induced rat vascular smooth muscle cell proliferation. DiYiJun YiDa Xue Xue Bao. 2004;24:247–51
109. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab. 2013;15:677–89
110. Desai K, Wu L. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Recent Pat Cardiovasc Drug Discov. 2007;2:89–99
111. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005;6:453–74
112. Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans. 2007;35:853–6
113. Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl. 2007;106:S54–60
114. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res. 2010;61:482–8
115. Beltramo E, Berrone E, Tarallo S, Porta M. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol. 2008;45:131–41
116. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res. 2010;61:34–9
117. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des. 2008;14:487–95
118. Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs. 2006;66:2287–98
119. Miyata T, van Ypersele deStrihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin IIreceptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13:2478–87
120. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51:3274–82
121. Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60:1271–7
122. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the infl ammatory response to AGE in mesangial cells. Proc Natl Acad SciU S A. 2004;101:11767–72.